Research Could Offer New Defenses Against Anthrax
WASHINGTON, DC, October 24, 2001 (ENS) - Two groups of researchers have announced key features of how anthrax toxin destroys cells. In back to back papers in the journal "Nature," investigators identify how one part of the toxin gets into cells and how another part turns off one of the cell's major internal switches. The studies also show how at least one molecule can prevent the toxin from destroying cells.
Several types of anthrax exist, but researchers are most concerned with inhalation anthrax, which can occur after a person inhales a large number of bacterial spores. The spores move to the lungs where they germinate, producing a potent toxin.
"If you do not kill the anthrax bacterium soon after infection, the microbe has time to produce potentially fatal levels of toxin, against which current drugs are not likely to be effective," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which funded the two studies. "These reports greatly increase our understanding of how anthrax toxin destroys cells and offer promising ways to develop treatments for advanced disease by attacking the toxin itself."
Anthrax toxin has three parts. Two parts, edema factor (EF) and lethal factor (LF), can destroy cells from the inside or prevent them from working. A third component, protective antigen (PA), carries EF and LF into the cells.
In the new reports, the researchers asked two critical questions: What molecule on the surface of animal cells does PA use as a doorway, or receptor, for entry; and how does the LF toxin attach to and destroy its intracellular targets?
Through genetic analysis, Young, Collier and their colleagues identified a protein on the surface of animal cells that proved to be the anthrax toxin receptor, which they labeled ATR.
The researchers next identified the region of ATR where the toxin attached. Using this information they then produced a shortened, free floating version of the receptor that contained the toxin binding domain. When they mixed that receptor fragment with rodent cells and anthrax toxin in a test tube, the cells were completely protected from destruction.
"The soluble receptor worked as a decoy or sponge to absorb the toxin before it could attach to the ATR on the cells," explained Young. "Now that we know what the anthrax receptor looks like, researchers can screen large numbers of smaller molecules to see if they, too, can prevent the toxin from binding ATR and entering cells."
"Our short term goals are to study the mechanism of toxin uptake through ATR and to make enough of the toxin blocking form of the receptor so that it can be tested in animal systems," Young added. "A more long term application would be for pharmaceutical companies to use the receptor along with anthrax toxin to screen the millions of compounds they've already synthesized to identify toxin inhibitors."
Because MAPKK is a key molecular switch that controls a cell's internal communications, its destruction leads to death of the cell.
Robert Liddington, Ph.D., of The Burnham Institute in La Jolla, California led an international team of researchers in a study of the three dimensional structure of LF. The investigators took X-rays of LF as it attached to MAPKK, uncovering key details of the toxin's surface and how it binds in a specific way to its target protein.
"LF grabs on by means of a long groove in the toxin molecule," said Liddington. Finding a molecule that fits into the groove in the toxin could deactivate it, rendering it harmless.
"By understanding how LF attaches to MAPKK, we now have the information needed for rational drug design," Liddington explained.
The ability to construct new anti-toxin compounds based on known features of the protein rather than by randomly screening large numbers of compounds should hasten the development of new drugs to treat anthrax.
"The persistence of new and reemerging infectious diseases, brought about by natural events as well as the intentional release by those who seek to do harm, has long driven NIAID's commitment to studying many microbes, including the anthrax bacterium," said Fauci. "Current events are now showing the importance of scientific diligence."